

Non Hodgkin Lymphoma (NHL)

A study for patients with Non-Hodgkin's Lymphoma (GOYA)

A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)

Trial Status
Completed

Trial Runs In
1 Countries

Trial Identifier
NCT01287741 2010-024194-39
(EudraCT number)

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This open-label, randomized, parallel group study will evaluate the efficacy and safety of obinutuzumab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisolone or prednisone (CHOP) chemotherapy versus rituximab (MabThera/Rituxan) with CHOP in previously untreated participants with cluster of differentiation 20 (CD20)-positive diffuse large B-cell lymphoma (DLBCL). Participants will be randomized to receive either obinutuzumab 1000 milligrams (mg) intravenously (IV) every 21 days or rituximab 375 milligrams per square meter (mg/m²) IV every 21 days for 8 cycles, in addition to 6-8 cycles of CHOP chemotherapy IV every 21 days. Participants randomized to the obinutuzumab arm will receive an additional two doses on Days 8 and 15 of Cycle 1. Anticipated time on study treatment is 24 weeks.

F. Hoffmann-La Roche Ltd
Sponsor

Phase 3
Phase

NCT01287741 2010-024194-39 (EudraCT number)
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
18 years and over

Healthy Volunteers
No